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Abstract
Background: We previously reported that phorbol 12-myristate 13-acetate (PMA) treatment can induce the cardiac
differentiation of mesenchymal stem cells (MSCs). In the present study, we investigated how PMA induces cardiac
differentiation of MSCs, focusing on its effect on the transcription factors responsible for increased cardiac marker
gene expression.
Methods: Human MSCs (hMSCs) were treated with 1 μM PMA for 9 days. The expression of MSC markers and
cardiac markers in the PMA-treated hMSC, as well as the nuclear translocation of transcription factors, nuclear factor
of activated T cells (NFAT), and myogenic differentiation 1 (MyoD), was examined. Transcriptional activity of NFAT
was examined by utilizing a green fluorescent protein (GFP) vector containing NFAT motif of human interleukin-2
promoter. The effect of PMA on the expression of key cell cycle regulators was examined.
Results: PMA induces the transcriptional activity of NFAT and MyoD, which have been associated with increased
expression of cardiac troponin T (cTnT) and myosin heavy chain (MHC), respectively. Our data suggested that
protein kinase C (PKC) mediates the effect of PMA on NFAT activation. Furthermore, PMA treatment increased
cell-cycle regulator p27kip1 expression, suggesting that PMA triggers the cardiac differentiation program in MSCs by
regulating key transcription factors and cell cycle regulators.
Conclusions: The results of this study demonstrate the importance of NFAT activation during PMA-induced MSC
differentiation and help us to better understand the underlying mechanisms of small molecule-mediated MSC
differentiation so that we can develop a strategy for synthesizing novel and improved differentiation-inducing small
molecules.
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Introduction
One common stem cell-based therapy involves the in
vitro expansion of stem cells to acquire a sufficient num-
ber of cells and the re-introduction of these cells into
damaged tissues [1]. However, certain tissues, such as
the myocardium, require more than just a high number
of therapeutic cells. For example, unsynchronized
electric coupling between the transplanted cells and car-
diomyocytes can increase the proarrhythmic potential
[2]; therefore, therapeutic cells resembling native cardio-
myocytes would be preferred in terms of their functional-
ity after transplantation compared with undifferentiated
stem cells [3]. One method for inducing differentiation of
stem cells into a desired lineage is small molecule
treatment.
To date, various small molecules with different bio-
logical mechanisms have been utilized to induce the car-
diac differentiation of stem cells. For example, a specific
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p38 mitogen-activated protein kinase (MAPK) inhibitor
[4] and a bone morphogenetic protein (BMP) inhibitor
[5] induced the cardiac differentiation of embryonic
stem cells. Furthermore, several studies have demon-
strated that a number of small molecule inhibitors of
Wnt signaling promoted cardiomyogenesis in stem cells
[6–8]. We have also reported that phorbol 12-myristate
13-acetate (PMA), a well-known protein kinase C (PKC)
activator, induced the expression of cardiac marker
genes such as myosin heavy chain (MHC) and cardiac
troponin T (cTnT) in mesenchymal stem cells (MSCs),
thus demonstrating its potential as a cardiac differenti-
ation inducer [9]. Nevertheless, that particular previous
study lacked detailed explanations of the underlying
mechanisms of how PMA induces cardiac differentiation
in MSCs.
Since the small molecule-mediated regulation of pro-
tein expression is what renders the phenotypic change
toward a desired lineage of cells, it is reasonable to
hypothesize that PMA activates certain transcription fac-
tors that drive the expression of cardiac marker genes in
MSCs. Thus, in the present study, we investigated the ef-
fect of PMA on the activation of key transcription factors
to further clarify the underlying molecular mechanism of
PMA treatment during MSC differentiation.
The transcription factor myogenic differentiation 1
(MyoD) is an early marker of myogenic differentiation
and is known to regulate the expression of MHC [10].
MyoD has been reported to convert a variety of cells,
such as nerve, liver, and fat cells, to skeletal muscle,
demonstrating that it is a powerful master regulator of
myogenic differentiation [11]. Because PKC has been re-
ported to be required for β-catenin-indepenent activa-
tion of MyoD [12], it is possible that PMA-induced
activation of PKC subsequently enhances the transcrip-
tional activity of MyoD and results in increased MHC
expression in MSCs. Another cardiac marker, cTnT, is
reportedly regulated by nuclear factor of activated T cells
(NFAT) [13]. Similar to MyoD, the transcriptional activ-
ity of NFAT can also be regulated by PKC-mediated
phosphorylation [14]. Thus, the reported cardiac differ-
entiation ability of PMA may involve activation of these
transcription factors, namely MyoD and NFAT, and we
examined such a possibility in the present study. We in-
vestigated the effect of PMA on the activation status of
these transcription factors and its related mechanisms.
Materials and methods
Induction of cardiogenic differentiation
Human MSCs (hMSC; Lonza, Allendale, NJ, USA)
were seeded in 60-mm cell culture plates at a density
of 2 × 105 cells/plate, and PMA (Sigma-Aldrich Corp.,
St. Louis, MO, USA) was added to a final concentra-
tion of 1 μM. PMA powder was reconstituted in
ethanol to make 1 mM PMA stock solution. For treat-
ment, 1 mM PMA stock was 1:1000 diluted in culture
medium. hMSCs were cultured in DMEM-low glucose
(Thermo Fisher Scientific, Pittsburgh, PA, USA) sup-
plemented with 10 % fetal bovine serum. The medium
was replaced every 3 days with PMA treatment for
9 days.
Immunofluorescence
Cells were cultured in four-well slide chambers. The
cells were permeabilized using 0.1 % Triton X-100 for
10 min. Next, the cells were blocked for 1 h in a block-
ing solution (2 % bovine serum albumin and 10 % horse
serum in phosphate-buffered saline) and incubated with
cTnT (ab8295; Abcam, Cambridge, MA, USA), β-MHC
(ab15; Abcam) and CD90 antibodies (sc-6071; Santa
Cruz Biotechnology, Dallas, TX, USA). FITC-conjugated
mouse, rabbit, and goat secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
were used. Immunofluorescence was detected by confocal
microscopy (LSM710; Carl Zeiss Microscopy GmbH, Jena,
Germany).
Co-localization image analysis
The degree of co-localization was measured by ZEN
2009 Light Edition software that calculated the percent-
age of co-localized pixels relative to all pixels obtained.
Following Carl Zeiss Micro-imaging, the Pearson’s cor-
relation coefficient R (PCC) value was calculated. The
value for PCC can range from –1 to 1, and a value of 1
indicates that the fluorescence patterns of the two mole-
cules are perfectly matched [15].
Western blot assay
Equal amounts of proteins were separated by SDS-
PAGE. After blocking the membrane with 5 % skim milk
for 1 h at room temperature, the membranes were incu-
bated with primary antibodies against NFAT (sc-
271127), MyoD (sc-760), p-MARCKS (sc-101730), and
p27 (sc-528; all Santa Cruz Biotechnology), LaminB2
(sab2702205; Thermo Fisher Scientific), and β-actin
(A5316; Sigma-Aldrich Corp.) overnight at 4 °C. The
membrane was washed and incubated for 1 h at room
temperature with horseradish peroxidase-conjugated
secondary antibodies. The bands were detected by an
enhanced chemiluminescence (ECL) reagent (Santa Cruz
Biotechnology). The band intensities were quantified
using NIH Image J version 1.34e software.
Nuclear and cytoplasmic extraction
For nuclear and cytoplasmic extraction, NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Thermo Fisher
Scientific) were used according to the user manual pro-
vided by the manufacturer.
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Immunoprecipitation
For immunoprecipitation (IP), cells were lysed in IP lysis
buffer (Thermo Fisher Scientific) for 30 min on ice. Cell
lysates were centrifuged at 10,000 g for 20 min and the
supernatant was retained. After protein quantification,
the lysates were incubated with calcineurin A antibody
(ab3673; Abcam), and the tubes were rotated for 1 h at
4 °C. After 1 h, Protein G Dynabeads (Thermo Fisher
Scientific) were added to the lysates and incubated over-
night at 4 °C. The Dynabeads-antibody-calcineurin A
complexes were centrifuged at 2500 g for 30 min at 4 °C,
and the antibody-calcineurin A complexes were eluted
with elution buffer, and the eluted proteins were
heated for 10 min at 99 °C and subjected to SDS-PAGE
electrophoresis.
Construction of the pAc-NFAT-GFP vector and
transfection
To construct a green fluorescent protein (GFP) vector
containing the NFAT binding motif of human
interleukin-2 (GGAGGAAAAACTGTTTCATACAGAA
GGCGT, corresponding to –286/–257 of the human
interleukin-2 promoter [16]), two copies of the NFAT
binding motif were synthesized and cloned into the
pAcGFP1-1 (Clontech, Mountain View, CA, USA) vec-
tor using HindIII and BamHI enzymes. The constructed
GFP vectors were delivered to the cells using Lipofecta-
mine LTX (Thermo Fisher Scientific). For six-well plates,
500 ng/well of each vector was used.
RT-PCR
The expression levels of various genes were analyzed by
reverse transcription polymerase chain reaction (RT-
PCR). Complementary DNA (cDNA) was generated
using 500 ng of total RNA with the Promega Reverse
Transcription System according to the manufacturer’s
instructions. The PCR conditions consisted of denatur-
ing at 94 °C for 3 min, followed by 35 cycles of denatur-
ation at 94 °C for 30 s, annealing at 94 °C for 30 s, and
extension at 72 °C for 30 s, before a final extension at
72 °C for 10 min. RT-PCR products were separated by
electrophoresis on a 1.2 % agarose gel (Bio-Rad La-
boratories, Inc., Hercules, CA, USA). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as an
internal standard.
Statistical analysis
Quantitative data were expressed as the means ± SD of
at least three independent experiments. For statistical
analysis, one-way analysis of variance (ANOVA) with
Bonferroni correction was performed using OriginPro 8
SR4 software (ver. 8.0951, OriginLab Corporation,
Northampton, MA, USA) if there were more than three
groups. A p value of less than 0.05 was considered statis-
tically significant.
Result
PMA-induced cardiac marker expression in hMSCs
The cells were treated with PMA (1 μM) for 9 days
based on a previous report in which the same regime in-
duced the cardiac differentiation of rMSCs [9]. After
9 days of PMA treatment, the expression levels of the
cardiac-specific markers cTnT and MHC increased in
the PMA-treated group compared with those of the un-
treated control (Fig. 1a, b). On the other hand, the ex-
pression of the stem cell marker CD90 decreased with
PMA treatment compared with that of the untreated
control (Fig. 1c). Additionally, the RT-PCR result indi-
cated that PMA increased the expression of both MHC
and cTnT at the RNA level compared to control (Fig. 1d).
These data suggested that PMA treatment induced the
differentiation of hMSCs into cells with cardiomyocyte
characteristics.
PMA induced activation of the transcription factors NFAT
and myoD
Nuclear translocation of MyoD and NFAT is a pre-
requisite for them to have transcriptional activity. There-
fore, we examined the subcellular distribution of these
transcription factors in hMSCs after PMA treatment.
The results of Western blot analysis indicated that the
amounts of NFAT and MyoD in the nuclear fraction in-
creased with PMA treatment (Fig. 2a). However, the pat-
tern of the increase was different. The nuclear
localization of NFAT gradually increased from day 1 to
day 3 and slightly decreased at day 6 in the PMA-treated
group. Nevertheless, the amount of nuclear localized
NFAT was still higher than that of the control group.
On the other hand, the amount of nuclear MyoD in-
creased on day 1, and then decreased thereafter. This
suggested that the effect of PMA may have been medi-
ated mainly by NFAT rather than by MyoD.
We performed immunocytochemical staining using
antibodies specific to the transcription factors. In un-
treated control hMSCs, both NFAT and MyoD were
evenly distributed without prominent accumulation in
the nucleus. However, when the cells were treated with
PMA for 3 days, the amount of the transcription factors
observed in the nucleus increased noticeably (Fig. 2b, c).
To quantify the nuclear localization of both transcrip-
tion factors, we further conducted a co-localization ana-
lysis for the transcription factors and DAPI-stained
nuclei. The result indicated that PMA significantly in-
creased the amount of both transcription factors that
reside in the nucleus (Fig. 2d). The degree of co-
localization was greater for NFAT than MyoD as evi-
denced by the higher PCC value.
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PMA increased calcineurin/calmodulin A interaction and
ser9 phosphorylation of GSK3β
The nuclear localization of NFAT was more pronounced
than that of MyoD after PMA treatment, and this result
may indicate that the effect of PMA was mainly medi-
ated by NFAT. Thus, we further examined the under-
lying mechanisms of PMA with a focus on NFAT.
Dephosphorylation of NFAT by phosphatases, such as
calcineurin, and the subsequent nuclear translocation of
NFAT increases its transcriptional activity [17]. Because
the interaction with calmodulin facilitates the activation
of calcineurin [18], we examined the interactions be-
tween calmodulin and calcineurin using the IP method.
After 12 h of PMA (1 μM) treatment, the interaction
between calcineurin A and calmodulin increased com-
pared with that of the control, suggesting that PMA in-
duced calmodulin-dependent activation of calcineurin A
(Fig. 3a). To examine whether myristoylated alanine-rich
C kinase substrate (MARCKS) contributed to this PMA-
induced interaction of calcineurin and calmodulin, we
checked the effect of PMA on MARCKS phosphorylation.
PMA increased phosphorylation of MARCKS up to the
first 6 h and then the phosphorylation returned to baseline
after 12 h (Fig. 3b), demonstrating that PMA-induced
phosphorylation of MARCKS may have contributed to the
increased calcineurin-calmodulin interaction. Another
possible mechanism may involve inactivation of glycogen
synthase kinase 3 beta (GSK3β), which facilitates the
phosphorylation of NFAT and subsequent nuclear exit
[19, 20]. According to our data, PMA increased the phos-
phorylation of GSK3β at serine 9, which indicated greater
inactivation of GSK3β [21] compared with that of the un-
treated control (Fig. 3c). Although the amount of phos-
phorylated GSK3β in the cytoplasmic fraction peaked at
day 1 and decreased thereafter, it was still pronounced
until day 6 compared with the control.
PMA induced the transcriptional activity of NFAT
We constructed a GFP vector containing the NFAT
binding motif of human interleukin-2 promoter (pAc-
NFAT-GFP; Additional file 1: Figure S1A). When pAc-
NFAT-GFP (500 ng/well, six-well plate)-transfected Hela
cells were treated with 1 μM PMA for 24 h, the expres-
sion of GFP was pronounced compared with that of ve-
hicle (DMSO)-treated pAc-NFAT-GFP-transfected cells
(Additional file 1: Figure S1B). This result suggested that
PMA induced the nuclear translocation and subsequent
transcriptional activation of NFAT.
PMA induced p27 upregulation and proliferation arrest
Temporal antagonism between cell cycle exit and differ-
entiation has been demonstrated in cultured cells and
animal models [22]. Discovered as an inhibitor of cyclin
E/CDK2 (cyclin-dependent kinase 2) [23], the cyclin-
dependent kinase inhibitor 1B (p27kip1) is a cell cycle in-
hibitor protein that stops or slows down the cell division
Fig. 1 Expression of cardiac and stem cell markers in PMA-treated hMSCs. Immunocytochemical analysis was performed to detect the expression
of a cTnT (scale bar = 100 μm), b β-MHC (scale bar = 100 μm), and c CD90 (scale bar = 40 μm) at 9 days after PMA (1 μM) treatment. DAPI was
used to stain the nucleus. d mRNA expression of β-MHC and cTnT in hMSCs treated with PMA for 9 days was detected by RT-PCR. *p < 0.05,
versus control. cTnT cardiac troponin T, MHC myosin heavy chain, PMA phorbol 12-myristate 13-acetate
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cycle. Because NFAT-mediated regulation of p27kip1 has
been reported [24, 25], we also examined the effect of
PMA on the expression of p27kip1 and cellular prolifera-
tion. Our data indicated that PMA treatment increased
the expression of p27kip1 at both the RNA (Fig. 4a) and
protein (Fig. 4b) levels. Furthermore, PMA significantly
decreased the expression of proliferating cell nuclear
antigen (PCNA), suggesting that PMA induced cell cycle
arrest in hMSCs (Fig. 4c).
Discussion
Here we demonstrated that NFAT is a key factor that
mediates PMA-induced cardiac differentiation of
hMSCs. In resting cells, the NFAT regulatory domain is
phosphorylated by different kinases, including GSK3
[26–28]. This phosphorylation of the NFAT is important
for the activation of NFAT because the phosphorylation
status facilitates NFAT nuclear translocation [29]. Multi-
phosphorylation at this domain masks the nuclear
localization sequence (NLS) of NFAT, resulting in its
cytoplasmic localization [30]. Therefore, either promot-
ing the dephosphorylation of NFAT or suppressing its
phosphorylation, or both, can lead to nuclear transloca-
tion and subsequent transcriptional activation of NFAT.
Our data suggest that PMA is involved in both of these
mechanisms.
PMA is an activator of PKC [31], and activated PKC
can both stimulate dephosphorylation and inhibit phos-
phorylation of NFAT. First, the PKC-dependent stimula-
tion of NFAT dephosphorylation can be achieved by
regulating calmodulin-calcineurin interactions. MARCKS
is a PKC substrate that has a calmodulin-binding domain
[32], and it is reportedly expressed in MSCs [33]. Upon
phosphorylation by PKC, MARCKS dissociates from
Fig. 2 PMA-induced nuclear translocation of MyoD and NFAT in hMSCs. a The amount of NFAT and MyoD in the nuclear/cytosolic fraction was
examined by Western blot to evaluate the nuclear localization of those transcription factors after PMA (1 μM) treatment. Lamin B2 served as a
nuclear control (Cont). b hMSCs treated with PMA were fixed at day 9 and analyzed by immunofluorescence staining using antibodies against
b NFAT (scale bar = 40 μm) and c MyoD (scale bar = 100 μm). DAPI was used to stain the nucleus. d Calculated co-localization of NFAT and MyoD
(shown in pink; scale bar = 40 μm). *p < 0.05, versus control. D1 1 day after PMA treatment, D3 3 days after PMA treatment, D6 6 days after PMA
treatment, MyoD myogenic differentiation 1, NFAT nuclear factor of activated T cells, PCC Pearson’s correlation coefficient, PMA phorbol
12-myristate 13-acetate
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calmodulin [34]. This result suggests that phosphorylation
of MARCKS by PKC can lead to a significant increase in
the local concentration of ‘free’ calmodulin that can bind
to calcineurin (Fig. 4d). Because binding calmodulin al-
lows calcineurin to exert its phosphatase activity [18], the
activation of PKC by PMA may lead to the dephosphory-
lation of NFAT via the phosphorylation of MARCKS and
a subsequent calmodulin/calcineurin interaction. In fact,
our data indicated that PMA induced phosphorylation of
MARCKS supporting MARCKS-mediated calcineurin/cal-
modulin interaction.
On the other hand, the activation of PKC may result
in the suppression of NFAT phosphorylation by modu-
lating GSK3β activity. Our data clearly demonstrated
that PMA induced the phosphorylation of GSK3β
(Fig. 3b), which is most likely mediated by PMA-
activated PKC [35]. One thing should be noted: there
was a transient upregulation of GSK3β after PMA treat-
ment, with unknown mechanisms. Even after an exten-
sive literature search the exact mechanism could not be
found. However, since the activity of GSK3β is mainly
regulated by its phosphorylation rather than expression
itself, as long as PMA treatment increased the phosphor-
ylation of GSK3β, transient upregulation of GSK3β
would not have significantly affected the result of this
study.
Because the phosphorylation of GSK3β at Ser9 inhibits
the kinase activity of GSK3β [21], the PMA-induced
phosphorylation of GSK3β may decrease the possibility
for NFAT phosphorylation by GSK3β. In turn, the de-
creased phosphorylation of NFAT results in the in-
creased transcriptional activity of NFAT (Fig. 4d).
Although it is difficult to state that NFAT is the single
most important transcription factor driving PMA-
mediated cardiac differentiation of MSCs, our study pro-
vides sufficient evidence that PMA activates the tran-
scriptional activity of NFAT and a logical explanation for
how PMA treatment leads to the transcriptional activa-
tion of NFAT. Although the GSK3β pathway and cal-
modulin pathway are discussed separately, there is also
high possibility that those two pathways interact at some
point to concert the effect of PMA. As far as we know,
there is no previous study that has either proved or
disproved GSK3β and calmodulin (or calcineurin)
Fig. 3 PMA increases calmodulin-calcineurin interactions and phosphorylation of GSK3β. a hMSCs treated with PMA (1 μM) for 12 h were
immunoprecipitated with anti-calcineurin A. The cell lysates and immunoprecipitates were analyzed by Western blot using the indicated antibodies.
b The effect of PMA on phosphorylation of MARCKS. The phosphorylation status of MARCKS for the first 12 h of PMA treatment was examined by
Western blot using p-MARCKS specific antibodies. c The amount of p-GSK3β in the nuclear/cytoplasmic fraction was examined by Western blotting
after PMA (1 μM) treatment. Lamin B2 was used as a loading control for the nuclear fraction. *p < 0.05, versus control. c control, D1 1 day after PMA
treatment, D3 3 days after PMA treatment, D6 6 days after PMA treatment, GSK3β glycogen synthase kinase 3 beta, IP immunoprecipitation, MARCKS
myristoylated alanine-rich C kinase substrate, PKC protein kinase C, PMA phorbol 12-myristate 13-acetate
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interaction. Therefore, it would make a very interesting
subject for future study.
Small molecules have great potential in controlling stem
cell fate by regulating cellular processes such as prolifera-
tion, reprogramming and differentiation [36, 37]. In fact, a
number of small molecules have been utilized to differen-
tiate stem cells into cardiomyocytes [4–8], and it is ex-
pected that more small molecules will be tested for their
abilities to regulate stem cell differentiation. Therefore, it
is important to understand how small molecules induce
stem cell differentiation because elucidating the under-
lying mechanism enables us to develop a strategy for syn-
thesizing novel and improved differentiation-inducing
small molecules. From that point of view, our study pro-
vides valuable information on the cardiac differentiation
ability of PMA.
Conclusion
Our data demonstrated that the PKC activator PMA
induced transcriptional activity of NFAT via both
GSK3β-mediated pathway and calcineurin/calmodulin-
mediated pathway, leading to cardiac-specific marker
expression. The results of this study recapitulate the
importance of transcriptional regulation during MSC
differentiation and help us to better understand the
underlying mechanisms of small molecule-mediated
MSC differentiation.
Additional file
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